A

Aclaris Therapeutics
D

ACRS

2.73000
USD
-0.04
(-1.27%)
مغلق
حجم التداول
47,773
الربح لكل سهم
-1
العائد الربحي
-
P/E
-5
حجم السوق
195,006,472
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADCT
    -0.14500
    (-6.86%)
    1.97000 USD
    A
    AGEN
    0.07000
    (2.54%)
    2.83000 USD
    A
    ALXO
    0.12500
    (8.47%)
    1.60000 USD
    AMGN
    AMGN
    2.27
    (0.87%)
    263.46 USD
    A
    APPH
    0
    (0%)
    0.000000 USD
    A
    ASMB
    -0.340
    (-2.19%)
    15.160 USD
    A
    ATNX
    -0.34000
    (-19.65%)
    1.43000 USD
    B
    BCRX
    0.18000
    (2.44%)
    7.57000 USD
    BGNE
    BGNE
    1.300
    (0.74%)
    176.450 USD
    BIIB
    BIIB
    -0.780
    (-0.53%)
    146.590 USD
    B
    BPMC
    1.130
    (1.27%)
    90.120 USD
    C
    CRSP
    0.360
    (0.89%)
    40.720 USD
    GILD
    GILD
    1.460
    (1.60%)
    92.570 USD
    I
    INCY
    1.910
    (2.85%)
    68.910 USD
    MRK
    MRK
    -1.390
    (-1.40%)
    98.150 USD
    N
    NBRV
    0.04000
    (2.84%)
    1.45000 USD
    N
    NKTR
    -0.02540
    (-2.69%)
    0.92000 USD
    NVS
    NVS
    0.340
    (0.35%)
    97.070 USD
    P
    PTCT
    1.000
    (2.21%)
    46.200 USD
    T
    TBIO
    0
    (0%)
    0.000000 USD
    المزيد
الأخبار

العنوان: Aclaris Therapeutics

القطاع: Healthcare
الصناعة: Diagnostics & Research
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; andATI-1777.